Sugi Predict

Sugi Predict / Targets / IPO8

IPO8

Importin-8 · O15397 · IPO8 on Sugi Atlas →

16 patent compounds predicted against IPO8, 14 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL24532075 SCHEMBL24532075 0.89 2/20
SCHEMBL24532060 SCHEMBL24532060 0.77 2/20
SCHEMBL4698636 SCHEMBL4698636 0.76 2/20
SCHEMBL4696222 SCHEMBL4696222 0.72 2/20
SCHEMBL20439526 SCHEMBL20439526 0.68 2/20
SCHEMBL21942991 SCHEMBL21942991 0.66 2/20
SCHEMBL29728046 SCHEMBL29728046 0.64 2/20
SCHEMBL22025041 SCHEMBL22025041 0.63 2/20
SCHEMBL29728047 SCHEMBL29728047 0.63 2/20
SCHEMBL22025046 SCHEMBL22025046 0.55 2/20
SCHEMBL22024728 SCHEMBL22024728 0.52 2/20
SCHEMBL22025138 SCHEMBL22025138 0.52 2/20
SCHEMBL22024582 SCHEMBL22024582 0.47 2/20
SCHEMBL20376696 SCHEMBL20376696 0.34 2/20

Clinical trials — most relevant to IPO8 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Does Aldosterone Cause Hypertension by a Non-Renal Mechanism? PHASE4UNKNOWN
Hydroxychloroquine and Ivermectin for the Treatment of COVID-19 Infection PHASE3COMPLETED
Clinical Evaluation of the Effect of Metformin in Sepsis PHASE3UNKNOWN
Ivermectin and Nitazoxanide Combination Therapy for COVID-19 PHASE2/PHASE3UNKNOWN
A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL PHASE1/PHASE2RECRUITING
Selinexor With ICE Chemotherapy in Secondary Central Nervous System Involving B-cell Non-Hodgkin Lymphoma PHASE1/PHASE2RECRUITING
Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers PHASE1/PHASE2RECRUITING
Efficacy of Ivermectin in COVID-19 PHASE1/PHASE2COMPLETED
Phase I/II Safety Study of IPI-504 in Relapsed/Refractory Stage IIIb, or Stage IV Non-small Cell Lung Cancer (NSCLC) PHASE1/PHASE2COMPLETED
Personalized Antisense Oligonucleotide for a Single Participant With MAPK8IP3 Neurodevelopmental Disorder With or Without Variable Brain Abnormalities (NEDBA) PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Clinical Study of EBV-LMP1 Targeted DNAzyme to Treat Nasopharyngeal Carcinoma PHASE1/PHASE2COMPLETED
Melpida: Recombinant Adeno-associated Virus (serotype 9) Encoding a Codon Optimized Human AP4M1 Transgene (hAP4M1opt) PHASE1/PHASE2RECRUITING
Reverse Transcriptase Inhibitors in AGS PHASE2COMPLETED
Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma PHASE2RECRUITING
Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors PHASE1/PHASE2RECRUITING
Safety Study of IPI-504 in Patients With Relapsed and Relapsed Refractory Multiple Myeloma PHASE1COMPLETED
A Clinical Study on the Efficacy and Safety of Methotrexate (MTX) or Thiotepa (for MTX Intolerance) or Temozolomide (TMZ) Combined With Orelabrutinib and Selinexor in Relapsed/Refractory Primary or Secondary Central Nervous System Lymphoma（SELINA） nanRECRUITING
Role of the Nuclear Pore Component RANBP2 in Inflammatory Responses to Viral Infections nanCOMPLETED
Progressive Familial Intrahepatic Cholestasis in Indian Children - Establishing an Indian PFIC Registry nanUNKNOWN
Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis nanUNKNOWN
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
Prognostic Value of Protein IMP3 Expression in Cervical Cancer nanCOMPLETED
Genetic Investigation of Solid Tumors Cohort nanCOMPLETED
Genetic Study in Patients With Stage II or Stage III Colon Cancer nanCOMPLETED
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics nanUNKNOWN
Steroid Treatment of Idiopathic Nephrotic Syndrome nanCOMPLETED
MEHMO Natural History and Biomarkers nanRECRUITING
Cytomegalovirus (CMV) MicroRNA Expression in Vivo and Immune Evasion Correlates nanCOMPLETED
Effect of Periodontal Treatment on Inflammasome Proteins in Periodontal Diseases nanUNKNOWN
ADAR1 Expression Level in Rectal Cancer nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a IPO8 binder may also engage these)

ProteinNameSimilarity
IPO7 Importin-7 1.000 landscape →
Q9EPL8 — 1.000 Q9EPL8 →
Q7TMY7 — 0.998 Q7TMY7 →
IPO11 Importin-11 0.987 landscape →
A5WW24 — 0.987 A5WW24 →
XPO5 Exportin-5 0.987 landscape →
IPO5 Importin-5 0.985 landscape →
F4IRR2 — 0.985 F4IRR2 →
F4J738 — 0.985 F4J738 →
Q9CRT8 — 0.984 Q9CRT8 →
Q5SPJ8 — 0.983 Q5SPJ8 →
Q8BKC5 — 0.983 Q8BKC5 →
Q8GUL2 — 0.983 Q8GUL2 →
Q8K2V6 — 0.982 Q8K2V6 →
A5D785 — 0.981 A5D785 →
A0A0R4ITC5 — 0.980 A0A0R4ITC5 →
Q9ERK4 — 0.980 Q9ERK4 →
Q9BPX3 — 0.980 Q9BPX3 →
Q9GM44 — 0.980 Q9GM44 →
Q91YE6 — 0.980 Q91YE6 →
Q5ZLT0 — 0.979 Q5ZLT0 →
Q9TVC1 — 0.979 Q9TVC1 →
Q5R9G4 — 0.979 Q5R9G4 →
IPO9 Importin-9 0.979 landscape →
Q9PTU3 — 0.978 Q9PTU3 →
P42346 — 0.978 P42346 →
A4L9P7 — 0.978 A4L9P7 →
Q924C1 — 0.978 Q924C1 →
ATP6V1H V-type proton ATPase subunit H 0.978 landscape →
Q7SZC2 — 0.978 Q7SZC2 →